Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company’s lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Metrics to compare | CING | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCINGPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.1x | −2.3x | −0.4x | |
PEG Ratio | −0.05 | −0.04 | 0.00 | |
Price/Book | 27.8x | 2.0x | 2.6x | |
Price / LTM Sales | - | 1.8x | 3.2x | |
Upside (Analyst Target) | - | 98.7% | 50.5% | |
Fair Value Upside | Unlock | 11.5% | 5.9% | Unlock |